XML 70 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 23, 2017
Sep. 21, 2016
Mar. 01, 2016
Dec. 31, 2017
Nov. 30, 2017
Sep. 30, 2017
Jan. 31, 2017
Aug. 31, 2016
Apr. 30, 2016
Nov. 30, 2015
Aug. 31, 2015
Mar. 31, 2015
Jun. 30, 2014
Feb. 29, 2012
Jan. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2013
Dec. 31, 2007
Jul. 31, 2016
Jul. 31, 2015
Deferred Revenue Arrangement [Line Items]                                                
Potential future additional payments for development milestones                                   $ 305,500,000            
Liability related to refundable upfront payment       $ 0                           0 $ 12,500,000          
Settlement Agreement with Allergan, Inc and Map Pharmaceuticals, Inc [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Deferred revenue       0                           0            
License revenue received related to share of payments due                                   11,000,000            
Gain on settlement agreement represents reimbursement of legal expenses                                   $ 4,000,000            
Nektar's [Member] | NKTR-358 [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Percentage of sharing in Phase 2 development costs 25.00%                                              
Nektar's [Member] | AstraZeneca-Kirin [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Percentage of upfront payment, market access milestones, royalties and sales milestones     40.00%                                          
Eli Lilly and Company [Member] | NKTR-358 [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment           $ 150,000,000                                    
Percentage of sharing in Phase 2 development costs 75.00%                                              
Regulatory milestones payment, description                                   A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.            
Revenue related to Phase 1 clinical development and drug development activities                                   $ 4,200,000            
Eli Lilly and Company [Member] | NKTR-358 [Member] | License [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                                   125,900,000            
Revenue related to license activities                                   125,900,000            
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                                   17,600,000            
Eli Lilly and Company [Member] | NKTR-358 [Member] | Drug Product Development [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                                   6,500,000            
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development and Drug Product Development [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Deferred revenue       19,900,000                           19,900,000            
Eli Lilly and Company [Member] | NKTR-358 [Member] | Maximum [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Potential future additional development and regulatory milestones $ 250,000,000                                              
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Percentage of development milestones payments, to be received may be reduced under certain conditions 50.00%                                              
Percentage of development milestones payments, to be received will be reduced if conditions occur 75.00%                                              
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Maximum [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Percentage of funding phase 3 development costs on an indication by indication basis borne 25.00%                                              
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Minimum [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Percentage of funding phase 3 development costs on an indication by indication basis borne 0.00%                                              
Ophthotech Corporation [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Advance payment from collaboration partner             $ 12,700,000                                  
Ophthotech Corporation [Member] | Reagent Shipments [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Advance payment from collaboration partner for reagent shipments             $ 10,400,000                                  
Ophthotech Corporation [Member] | Minimum Purchase Requirement [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Advance payment from collaboration partner                                   2,300,000            
Ophthotech Corporation [Member] | Fovista [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Recognition of remaining deferred revenue                                   18,000,000            
Ophthotech Corporation [Member] | Fovista [Member] | Novartis Pharma AG [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                         $ 19,800,000                      
Bayer Healthcare LLC [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                                           $ 40,000,000    
Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                                         $ 30,000,000      
Recognition of remaining deferred revenue                                   16,800,000            
Baxalta Incorporated [Member] | ADYNOVATE (Hemophilia) [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Deferred revenue       1,000,000                           1,000,000            
Development milestones achieved                   $ 10,000,000                            
Received under right to sublicense agreement         $ 12,000,000                                      
Allocated consideration for ongoing supply obligation                                   1,000,000            
Consideration received for right to sublicense                                   11,000,000            
Baxalta Incorporated [Member] | ADYNOVATE (Hemophilia) [Member] | European Union [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Potential future additional payments for development milestones                                   10,000,000            
MAP Pharmaceuticals, Inc. [Member] | MAP-Allergan, Inc. [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement                             $ 80,000,000                  
Allergan, Inc. [Member] | Settlement Agreement with Allergan, Inc and Map Pharmaceuticals, Inc [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Payment received under settlement agreement for relief of claims related to share                                   15,000,000            
Amgen, Inc. [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                               $ 50,000,000                
Deferred revenue       14,200,000                           14,200,000            
AstraZeneca AB [Member] | United States [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Liability to AZ for DTC advertising payments                       $ 10,000,000                     $ 5,000,000 $ 5,000,000
Reduction of revenue                                       $ (10,000,000)        
AstraZeneca AB [Member] | MOVANTIK and MOVANTIK fixed-dose combination program [Member] | Upfront Payment Arrangement [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                                 $ 125,000,000              
AstraZeneca AB [Member] | MOVANTIK Fixed-dose Combination Program [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Potential contingent payments based on development events       75,000,000                           75,000,000            
AstraZeneca AB [Member] | MOVANTIK [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                       $ 100,000,000                        
AstraZeneca AB [Member] | MOVANTIK [Member] | European Union [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                     $ 40,000,000                          
AstraZeneca AB [Member] | AstraZeneca-Kirin [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                 $ 28,000,000                 4,600,000 33,000,000          
Deferred revenue       0                           0            
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement     $ 70,000,000                                          
Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner     60.00%                                          
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Refundable upfront payment paid       12,500,000                           12,500,000            
Liability related to refundable upfront payment                                     12,500,000          
Non-refundable portion of upfront payment                                     7,500,000          
Revenue recognized from upfront payment                                     3,700,000          
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | Upfront Payment Arrangement [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment               $ 20,000,000                                
Recognition of remaining deferred revenue                                   $ 3,200,000            
Roche [Member] | MIRCERA [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Consideration received for product delivered                                         $ 18,600,000      
Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Received upfront and milestone payment                           $ 27,000,000                    
Roche [Member] | PEGASYS and MIRCERA [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Deferred revenue                                     $ 0          
Bristol-Myers Squibb [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Strategic collaboration agreement date                                   Feb. 13, 2018            
Bristol-Myers Squibb [Member] | NKTR-214 [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Percentage of out-of-pocket costs reimbursed by partner   50.00%                                            
Payments received for reimbursement of costs                                   $ 7,800,000            
License agreement exclusivity expiration date                                   Sep. 30, 2018            
License agreement exclusivity negotiation period                                   3 months            
Other [Member]                                                
Deferred Revenue Arrangement [Line Items]                                                
Potential future additional payments for development milestones                                   $ 45,500,000            
Deferred revenue       $ 2,900,000                           $ 2,900,000